CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 171 enrolled
Drug / intervention
gatifloxacin +1 moredrug
Likely dose
Gatifloxacin or moxifloxacin 0.5% eye drops: 1 drop three times daily for 6 daysAI-extracted
Key inclusion· 1
  • ✓Diagnosed with bacterial conjunctivitis
Key exclusion· 4
  • ✕Chemical or foreign body trauma to either eye
  • ✕Any infection in either eye besides bacterial conjunctivitis
  • ✕White spots (keratitis) in the cornea or corneal ulcers in either eye
  • ✕Clinical diagnosis of chlamydia or gonorrhea in either eye

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00464438
NCT00464438Phase 4Completed
CompareCT.gov

A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis

Allergan·interventional·Posted Apr 23, 2007·Updated Sep 21, 2011

In Brief

A Phase 4 clinical trial evaluating gatifloxacin and moxifloxacin 0.5% eye drops for Bacterial Conjunctivitis. Completed, enrolled 171 participants across 2 sites in 2 countries.

Detailed Summary

This is a 7 day study to evaluate the safety and efficacy of topical gatifloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in subjects from birth to 31 days of age

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Conjunctivitis
CountriesCanada, United States
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 23, 2007
Enrollment StartJun 1, 2007
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.2 years ago

Interventions

gatifloxacindrug

Day 1-6 = 1 drop of study medication three times a day

moxifloxacin 0.5% eye dropsdrug

Day 1-6 = 1 drop of study medication three times a day